Success Metrics

Clinical Success Rate
72.6%

Based on 159 completed trials

Completion Rate
73%(159/219)
Active Trials
142(32%)
Results Posted
97%(154 trials)
Terminated
60(14%)

Phase Distribution

Ph phase_3
93
21%
Ph phase_4
24
5%
Ph not_applicable
13
3%
Ph phase_2
198
45%
Ph early_phase_1
6
1%
Ph phase_1
104
24%

Phase Distribution

110

Early Stage

198

Mid Stage

117

Late Stage

Phase Distribution438 total trials
Early Phase 1First-in-human
6(1.4%)
Phase 1Safety & dosage
104(23.7%)
Phase 2Efficacy & side effects
198(45.2%)
Phase 3Large-scale testing
93(21.2%)
Phase 4Post-market surveillance
24(5.5%)
N/ANon-phased studies
13(3.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

69.4%

159 of 229 finished

Non-Completion Rate

30.6%

70 ended early

Currently Active

142

trials recruiting

Total Trials

441

all time

Status Distribution
Active(161)
Completed(159)
Terminated(70)
Other(51)

Detailed Status

Completed159
Recruiting81
Active, not recruiting61
Terminated60
unknown47
Not yet recruiting17

Development Timeline

Analytics

Development Status

Total Trials
441
Active
142
Success Rate
72.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 16 (1.4%)
Phase 1104 (23.7%)
Phase 2198 (45.2%)
Phase 393 (21.2%)
Phase 424 (5.5%)
N/A13 (3.0%)

Trials by Status

completed15936%
terminated6014%
withdrawn102%
recruiting8118%
active_not_recruiting6114%
not_yet_recruiting174%
suspended41%
unknown4711%
enrolling_by_invitation20%

Recent Activity

Clinical Trials (441)

Showing 20 of 441 trialsScroll for more
NCT02003222Phase 3

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT06425302Phase 2

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

Active Not Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT02981628Phase 2

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT06172296Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Recruiting
NCT05645718Phase 2

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting
NCT07634471Phase 2

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

Recruiting
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT02112916Phase 3

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Active Not Recruiting
NCT02101853Phase 3

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT02306161Phase 3

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Active Not Recruiting
NCT06124157Phase 2

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT00092222Phase 2

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

Active Not Recruiting
NCT07724457Phase 2

Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma

Not Yet Recruiting
NCT07654426Phase 2

The CARDIOPROTECT Trial

Recruiting
NCT07719855Phase 3

A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma

Not Yet Recruiting
NCT06721689Phase 1

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

Recruiting
NCT06528496Phase 2

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Recruiting
NCT06091865Phase 3

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Recruiting
NCT02143414Phase 2

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
441